艾美疫苗

6660.HK

Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司是一家覆盖人用疫苗研发、生产及商业化全产业链的疫苗企业，业务涵盖疫苗产品的研究开发、工艺开发、注册申报、规模化生产及市场销售等全流程环节。公司依托病毒疫苗、基因工程疫苗、细菌疫苗、mRNA疫苗及联合疫苗等五大技术平台持续开展多品类疫苗产品研发及产业化布局，已形成覆盖多种技术路线和疾病领域的研发、制造及商业化体系。公司坚持商业化产品、迭代升级产品及创新疫苗协同发展的经营策略，在巩固狂犬病、乙肝、甲肝及流脑等现有产品市场基础上，持续推进迭代狂犬病疫苗、肺炎球菌疫苗、联合疫苗及mRNA创新疫苗等重点产品研发和注册进程。未来，公司将依托五大技术平台及产业化体系，持续开展疫苗产品创新和技术升级，不断完善覆盖多疾病领域、多技术路线的产品矩阵，提升公司的持续创新能力和综合竞争力。

ESG Score Industry Ranking:
9 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

AAA

7.88%

24.24%

27.88%

BBB

26.06%

10.91%

1.21%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.12Updated on 2026-10-29

08.1210

Management & Practices Score：5.12Updated on 2026-08-28

05.127

Controversies Score：3.00Updated on 2026-10-29

03.003

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	6.39	3.67	12.53%
Social	7.37	4.54	57.57%
Governance	7.57	5.78	29.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(165 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	603392.SH	万泰生物	AA	8.86	2.96	5.90	7.57	8.54	8.58
2	002252.SZ	上海莱士	AA	8.68	2.99	5.69	7.75	8.12	8.29
3	1801.HK	信达生物	AA	8.62	3.00	5.62	7.78	8.03	8.12
4	300142.SZ	沃森生物	AA	8.42	2.94	5.48	5.48	8.14	8.21
5	2269.HK	药明生物	AA	8.28	3.00	5.28	8.45	7.47	7.29
6	1530.HK	三生制药	AA	8.26	2.99	5.26	7.56	7.43	7.68
7	920344.BJ	三元基因	AA	8.16	2.96	5.20	4.33	7.97	7.69
7	300122.SZ	智飞生物	AA	8.16	2.97	5.19	5.40	7.42	8.24
9	6660.HK	艾美疫苗	AA	8.12	3.00	5.12	6.39	7.37	7.57
10	6855.HK	亚盛医药	AA	8.11	2.99	5.12	7.21	7.73	6.59